Discovery and Biosynthesis of the Novel Glycotetrapeptide Antibiotic Biffamycin A
Michael W Brigham1, Edward S Hems2,3, Daniel C L Van1
1Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.
Abstract:
The clinical deployment of antibiotics is undermined by antimicrobial resistance. Without new agents to treat antibiotic-resistant bacterial infections, mortality rates are predicted to reach 10 million people per year by 2050. Most antibiotics are derived from natural products (NPs) produced by bacteria; however, this resource was abandoned by industry because of high rediscovery rates. We are amid a natural product renaissance fuelled by inexpensive access to genome sequencing and sophisticated bioinformatic tools, which have highlighted that most of the biosynthetic pathways for NPs are not expressed in the laboratory. Here, we engineered the expression of a silent biosynthetic gene cluster harboured by an environmental isolate of Streptomyces albidoflavus. Using a bioinformatics-guided approach, we isolated and structurally characterised a novel glycopeptide antibiotic (GPA) named biffamycin A, which is the smallest GPA known and harbours unprecedented 5-chloro-4-methoxy tryptophan and 3-hydroxy(α-D-mannoysl)-D-lysine moieties. Biffamycin A possesses antimycobacterial and antistaphylococcal bioactivity, including against methicillin- and vancomycin-resistant Staphylococcus aureus.
More Related Videos
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Production of Antibiotics
Biosynthesis in Bacteria
Peptidoglycan Synthesis
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...


